Eyebright Medical Published its 2024 Environmental, Social and Governance Report
Commitment to Sustainable Development, Social Responsibility, and Corporate Governance HONG KONG, April 23, 2025 /PRNewswire/ -- Eyebright Medical Technology ( Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collectively known as the "...
Eyebright Medical Receives NMPA Class III Certificate for its Phakic Intraocular Lens
HONG KONG, Jan. 7, 2025 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collectively known as the "Group") is proud to announce that our Phakic intraocular lens, "Loong Crystal PR", has rec...
Eyebright Medical Continues to Employ Its Internationalization Strategy: Signed Memorandum with Invest Hong Kong and Spotlight at ESCRS 2024
HONG KONG, Sept. 24, 2024 /PRNewswire/ -- Eyebright Medical Technology (Beijing ) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collectively known as the "Group") is pleased to announce the recently development of its internationalization stra...
Eyebright Medical Announces Strong First Half 2024 Results, with Revenue Surpassing 68% Growth and Net Profit Rising by Nearly 30%
HONG KONG, Aug. 22, 2024 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Ltd ('Eyebright Medical'; the 'Company'; SH Stock Code: 688050), the first domestic manufacturer of high-end refractive intraocular lenses inChina, today announced its financial results for the first half of 2024. Th...
